There are not many patients with MET mutation, but the prognosis is bad, so a treatment is urgently needed. It was found that the HIRA began a benefit review for targeted treatments for MET mutants, which appear in 3-4% of all non-small cell lung cancer patients.

The MET mutation target anticancer drug landed in Korea in November last year with the approval of Novartis' Tabrecta and Merck's Tepmeko. Currently, it can be used as a non-reimbursement.

According to the industry on the 17th, the HIRA has begun a process to determine the appropriateness of Tabrecta's benefit. Tabrecta was granted domestic permission on November 23 last year. It is the first drug used in patients with local prog